Shao-Rui Chen

Shao-Rui Chen

Auto-generated profile, based on publicly available information

Shao-Rui Chen

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MDMeichun Deng
Meichun Deng
SCShao-Rui Chen
Shao-Rui Chen
MZMeng-Hua Zhou
Meng-Hua Zhou
JZJixiang Zhang
Jixiang Zhang
YHYuying Huang
Yuying Huang
HPHui-Lin Pan
Hui-Lin Pan
Amplification of nociceptive transmission due to aberrant N -methyl- d -aspartate receptor (NMDAR) hyperactivity in the spinal cord is a key characteristic of neuropathic pain. However, under normal conditions, both presynaptic and postsynaptic NMDARs in the spinal dorsal horn are largely inactive. The mechanisms restraining synaptic NMDAR activity remain enigmatic. Leucine-rich repeat-containing protein 8A (LRRC8A or SWELL1) is an essential component of volume-regulated anion channels typically involved in regulating cell volume. Here, we report that LRRC8A was highly expressed in dorsal root ganglion (DRG) and spinal dorsal horn neurons of rats. Nerve injury persistently reduced LRRC8A expression in the DRG. siRNA-mediated Lrrc8a knockdown in rats or conditional Lrrc8a knockout in DRG neurons in mice consistently caused a pain hypersensitivity phenotype that was readily reversed by NMDAR antagonists. Correspondingly, Lrrc8a knockdown or conditional Lrrc8a knockout in DRG neurons markedly augmented synaptic localization and activity of NMDARs in the spinal cord. LRRC8A interacted with NMDARs in both rat and human spinal cord tissues primarily through its C-terminal LRR domain, restricting the synaptic trafficking and activity of NMDARs. Furthermore, Lrrc8a ebo/ebo mutant mice, which lack the LRR domain, exhibited NMDAR-dependent pain hypersensitivity and synaptic NMDAR hyperactivity in the spinal cord. Additionally, intrathecal Lrrc8a gene delivery eliminated nerve injury–induced pain hypersensitivity and synaptic NMDAR hyperactivity in rats. These findings reveal that LRRC8A physically interacts with NMDARs and constitutively restricts their synaptic expression in the spinal cord. Reduced LRRC8A-NMDAR interactions increase synaptic expression of “unleashed” NMDARs, contributing to NMDAR hyperactivity and neuropathic pain in rodent models.

2 September 2025 in Science Signaling
Verified
Journal Article
Closed access
DJDaozhong Jin
Daozhong Jin
HCHong Chen
Hong Chen
MZMeng-Hua Zhou
Meng-Hua Zhou
YHYuying Huang
Yuying Huang
SCShao-Rui Chen
Shao-Rui Chen
HPHui-Lin Pan
Hui-Lin Pan
Opioids relieve pain by activating μ-opioid receptors (MORs), which inhibit communication between pain-sensing neurons (nociceptors) and the spinal cord. However, prolonged opioid use can paradoxically lead to increased pain sensitivity (hyperalgesia) and reduced analgesic efficacy (tolerance), partly because of the activation of NMDA-type glutamate receptors (NMDARs) at the central terminals of primary sensory neurons in the spinal cord. Here, we identified a critical role for the G protein Gα q in this paradox. Pharmacological inhibition of Gα q in rats reversed morphine-induced increases in NMDAR phosphorylation, synaptic trafficking, and activity at sensory neuron terminals and reduced morphine-induced excitatory nociceptive input to spinal dorsal horn neurons. Morphine enhanced Gα q coupling specifically to metabotropic glutamate receptor 5 (mGluR5) dimers in the spinal cord. Furthermore, targeted knockdown of Gα q in dorsal root ganglion neurons in mice normalized NMDAR-related changes and prevented NMDAR-mediated synaptic potentiation triggered by MOR activation. In addition, either pharmacological or genetic disruption of Gα q signaling enhanced morphine’s analgesic effects while reducing hyperalgesia and tolerance. These findings reveal that Gα q signaling contributes to opioid-induced NMDAR hyperactivity at nociceptor central terminals by promoting MOR-mGluR5 cross-talk. Targeting this pathway may improve the safety and efficacy of opioid-based pain management.

27 January 2026 in Science Signaling
Verified
Journal Article
Closed access
NLNaijiang Liu
Naijiang Liu
XSXiaojie Shi
Xiaojie Shi
SCShao-Rui Chen
Shao-Rui Chen
HCHong Chen
Hong Chen
MSMaria Daniela Santi
Maria Daniela Santi
YYYi Ye
Yi Ye
Pain associated with oral cancer is debilitating. Opioids are the gold standard for cancer pain management, but tolerance and side effects limit their use. Epidermal growth factor receptor (EGFR) signaling is commonly amplified in oral tumors. Here, we found that EGFR activation contributed to both oral cancer pain and opioid tolerance by sensitizing trigeminal ganglion (TG) cells, the main sensory neurons innervating the face and mouth. EGFR ligands were secreted by oral squamous cell carcinoma (OSCC) cells and by peripheral glial cells cocultured with OSCC cells. In human OSCC and an orthotopic mouse model, EGFR was abundant in tumor-innervating TG nerves. Oral cancer pain and opioid tolerance in the mice were increased by EGFR ligands and reduced by EGFR inhibitors. In mice, the abundance of glutamate-type NMDA receptors (NMDARs) was also increased in both the TG and the brainstem. Upon activation by ligands or OSCC cell supernatant, EGFR phosphorylated the NMDAR subunit GluN2B, which increased electrical currents and sensitized pre- and postsynaptic NMDARs in the brainstem. This sensitization was also seen in the brainstems of mice receiving chronic morphine treatment and was mitigated by EGFR blockade. These findings suggest that EGFR-targeted cancer therapeutics may be repurposed to manage cancer pain and reduce opioid tolerance in patients with OSCC.

25 August 2026 in Science Signaling
Verified
Journal Article
Closed access
DJDaozhong Jin
Daozhong Jin
HCHong Chen
Hong Chen
YHYuying Huang
Yuying Huang
SCShao-Rui Chen
Shao-Rui Chen
HPHui-Lin Pan
Hui-Lin Pan
Sustained hyperactivity of synaptic NMDA receptors (NMDARs) in the spinal dorsal horn is a hallmark of chronic neuropathic pain. Here, we identified the kinase BRAF as a critical regulator of this process. Spinal nerve injury in rats induced the translocation of BRAF from the dorsal root ganglion (DRG) to spinal cord synaptosomes, which was associated with enhanced phosphorylation of the downstream kinases MEK and ERK. In addition, spinal cord injury increased the interaction between NMDARs and BRAF/MEK/ERK in spinal cord samples from rats and humans. Pharmacological inhibition or genetic ablation of BRAF in mouse DRG neurons reversed nerve injury–induced NMDAR phosphorylation, synaptic trafficking, and presynaptic and postsynaptic hyperactivity in the spinal dorsal horn. Furthermore, whereas pain hypersensitivity persisted in wild-type mice after nerve injury, it was transient and less severe in mice that either lacked BRAF in DRG neurons or were treated with BRAF pathway inhibitors. Conversely, expressing a constitutively active BRAF mutant in DRG neurons induced sustained nociceptive hypersensitivity, which was blocked by NMDAR antagonists, gabapentin, or an α2δ-1 C-terminal-interfering peptide. This was accompanied by increased NMDAR phosphorylation and enhanced pre- and postsynaptic activity in the spinal cord. These findings reveal that BRAF in sensory neurons promotes neuropathic pain by enhancing NMDAR phosphorylation and transsynaptic hyperactivity and suggest that BRAF inhibitors might be repurposed to treat neuropathic pain.

18 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JTJoanne Tuohy
Joanne Tuohy
Toshitsugu IshiharaToshitsugu Ishihara
Toshitsugu Ishihara
SGSudarshana Govindasamy
Sudarshana Govindasamy
RARamu Anandakrishnan
Ramu Anandakrishnan
JDJennifer Davis
Jennifer Davis
BCBlaise Costa
Blaise Costa
CNS4 is an agonist concentration-biased NMDAR modulator exhibiting GluN2 subtype-dependent activity. Here we evaluated the translational pharmacology of CNS4 across mice, rats, and client-owned surgical oncology dogs. In mice, CNS4 did not produce conditioned place preference, indicating lack of reward liability. CNS4 produced dose-dependent reductions in locomotor activity without motor impairment on accelerating rotarod testing. CNS4 also maintained body temperature 0.5–1°C above the vehicle group in mice and dogs, consistent with NMDAR-dependent thermoregulatory activity and contrasting with hypothermic effects reported for NMDAR channel blockers such as ketamine. In fear-conditioning paradigms, CNS4 did not impair fear learning, memory consolidation, or fear expression. CNS4 reduced acute stress-induced sucrose preference, suggesting modulation of stress-responsive neural circuits. In a rat spinal nerve ligation model of neuropathic pain, both single-dose and three-day repeated CNS4 administration significantly reversed mechanical, pressure, and thermal hypersensitivity, supporting analgesic efficacy with no apparent evidence of rapid tolerance development. In client-owned surgical oncology dogs undergoing standard veterinary procedures, preliminary findings from 14 dogs (8 CNS4-treated, 6 vehicle-treated) demonstrated stable intraoperative mean arterial pressure and heart rate. Postoperatively, CNS4-treated dogs exhibited normal physiological recovery, with respiratory rate, heart rate, and body temperature returning toward the normal canine range, and required approximately 8% less propofol for anesthetic induction. Collectively, these findings support CNS4 as a novel NMDAR modulator with thermoregulatory, anti-agitative, analgesic, and autonomic-stabilizing properties without evidence of abuse liability, supporting continued translational development for neuropathic pain and possibly neuropsychiatric disorders.